As GEP-44 advances through IND-enabling studies and toward eventual phase I trials, SureNano Science represents one of the relatively few microcap public companies providing direct exposure to the rapidly expanding GLP-1 market
Moreover, the higher obesity prevalence is projected to increase up to 1.13 billion by the end of 2030, illustrating that GLP-1 demand is not limited to large economies but includes diverse global regions
3 Fortunately, for patients who fail to achieve weight loss goals (at least 5% of total body weight in 3-6 months), pharmacotherapy (in conjunction with lifestyle changes) can make a key difference
A combination of skincare, healthy habits, and non-invasive treatments for facial wrinkles can support the skin during and after GLP-1 weight loss
Some patients prefer a non-medication approach built around nutrition coaching, metabolic testing, and lifestyle changes, while others combine both for faster results
The short answer is yes, with the same caveats that apply to all tirzepatide treatment
